Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
|Articles|November 19, 2021
In case you missed it: Nov. 15 to Nov. 19
Author(s)Lindsey Carr, Editor
It was a busy week for the Contemporary OB/GYN team.
Advertisement
This week's top articles included:
Building a framework for a multidisciplinary approach to chronic pelvic pain therapy
If you want to provide comprehensive care, it is truly impossible as 1 person,” began Jean Uy-Kroh, MD, FACOG, director, Chronic Pelvic Pain Program at the Cleveland Clinic in Cleveland, Ohio, at AAGL’s 50th Global Congress on MIGS in Austin, Texas.
Exploring the potential of AI for gynecologic surgery
Gaby Moawad, MD, FACOG, spoke about the benefits of using AI for minimally invasive gynecologic surgery and its future potential in the specialty.
The need for office hysteroscopies in your practice
“My hysteroscope is my stethoscope. I use it in every opportunity when the story doesn’t match,” Linda D. Bradley, MD, said during her presentation at AAGL’s 50th Global Congress on MIGS, “Office Hysteroscopy: Seeing is Believing. A Manifesto for Change.”
Advertisement
Related to this article
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
Neurokinin receptor antagonists improve menopausal sleep disturbance
3
Stephanie Faubion, MD, on the first menopause therapy discussion
4
Brain fog at menopause: Separating normal change from dementia
5